Drug Profile


Latest Information Update: 13 Jan 1999

Price : $50

At a glance

  • Originator Eli Lilly; Novo Nordisk
  • Developer Eli Lilly
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M2 receptor agonists; Muscarinic M3 receptor antagonists; Muscarinic M4 receptor agonists; Muscarinic M5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Psychotic disorders

Most Recent Events

  • 13 Jan 1999 New profile
  • 13 Jan 1999 Discontinued-Preclinical for Psychotic disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top